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The arenavirus family contains several important human pathogens including Lassa fever virus (LASV), lymphocytic choriomeningitis virus
(LCMV) and the New World clade B viruses Junin (JUNV) and Machupo (MACV). Previously, α-dystroglycan (α-DG) was identified as a
receptor recognized by LASVand certain strains of LCMV. However, other studies have suggested that α-DG is probably not used by the clade B
viruses, and the receptor(s) for these pathogens is currently unknown. Using pseudotyped retroviral vectors displaying arenavirus glycoproteins
(GPs), we are able to explore the role played by the GP in viral entry in the absence of other viral proteins. By examining the ability of the vectors
to transduce DG knockout murine embryonic stem (ES) cells, we have confirmed that LASV has an absolute requirement for α-DG in these cells.
However, the LCMV GP can still direct substantial entry into murine ES cells in the absence of α-DG, even when the GP from the clone 13
variant is used that has previously been reported to be highly dependent on α-DG for entry. We also found that neither LASV or LCMV
pseudotyped vectors were able to transduce human or murine lymphocytes, presumably due to the glycosylation state of α-DG in these cells. In
contrast, the JUNV and MACV GPs displayed broad tropism on human, murine and avian cell types, including lymphocytes, and showed no
requirement for α-DG in murine ES cells. These findings highlight the importance of molecules other than α-DG for arenavirus entry. An alternate
receptor is present on murine ES cells that can be used by LCMV but not by LASV, and which is not available on human or murine lymphocytes,
while a distinct and widely expressed receptor(s) is used by the clade B viruses.
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The arenaviruses are rodent-borne pathogens which include
five members classified by the Centers for Disease Control and
Prevention as Category A biological agents, capable of posing a
significant threat if used for bioterrorism purposes. Two major
subgroups are recognized on the basis of sequence comparisons,
the Old World and New World viruses, with the New World
viruses further divided into clades A, B and C (Fig. 1). The most⁎ Corresponding author. Department of Research Immunology and Bone
Marrow Transplantation, Childrens Hospital Los Angeles, 4650 Sunset
Boulevard, mailstop #62, Los Angeles CA 90027, USA. Fax: +1 323 660 8736.
E-mail address: pcannon@chla.usc.edu (P.M. Cannon).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.05.018common human infections are caused by the Old World viruses,
lymphocytic choriomeningitis virus (LCMV) and Lassa fever
virus (LASV). While LCMV infections are usually asymptom-
atic or mild, LASV infection is characterized by pulmonary
edema, respiratory distress, shock and bleeding from mucosal
surfaces. LASV infection rates are estimated at over 300,000 per
year, mostly in Western Africa. Serious illnesses are also
associated with certain New World clade B viruses, including
Junin (JUNV) and Machupo (MACV) viruses, the causative
agents of Argentine and Bolivian hemorrhagic fevers, respec-
tively. Since studies of the highly pathogenic arenaviruses are
hampered by the need for biosafety level (BSL)-4 containment
laboratories, most of the available information about this family
has come from studies of LCMV.
Fig. 1. The Arenaviridae. The family is divided into New World and Old World viruses, with the New World viruses further divided into three clades. The strains that
are pathogenic for humans are indicated.
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RNA viruses. Their entry into cells is directed by a fusion
glycoprotein (GP) located in the outer lipid envelope of the
virus. This protein is initially synthesized as a precursor
protein, GPC, which is cleaved into two non-covalently
linked subunits, an integral membrane protein, GP2, and a
peripheral membrane protein, GP1. The binding site for the
cellular receptor is contained within GP1 (Parekh and
Buchmeier, 1986), while GP2 anchors the complex in the
viral and host cell membranes (Burns and Buchmeier, 1991)
and contains structural features typical of class I viral fusion
proteins (Gallaher et al., 2001). We and others have
demonstrated that arenavirus GPs can be incorporated into
retroviral and lentiviral vector particles, generating functional
surrogates of the arenavirus entry process that can be worked
with under standard BSL-2 laboratory conditions (Beyer et
al., 2002; Christodoulopoulos and Cannon, 2001; Kunz et al.,
2003). The use of pseudotyped retroviral vectors also
simplifies the analysis of arenavirus entry as it is possible
to study the function of GP in the absence of other factors
that may influence infection by native viruses.
A cellular receptor for LASV, certain strains of LCMV and
the New World clade C arenaviruses Oliveros and Latino has
been identified as α-dystroglycan (α-DG) (Cao et al., 1998;
Kunz et al., 2005; Spiropoulou et al., 2002). This is a peripheral
membrane protein, non-covalently associated with β-DG, and
widely expressed in most cells, where it serves as an anchor
between the submembranous cytoskeleton and the extracellular
matrix (Durbeej et al., 1998). Recently, it has been shown that
the specific post-translational glycosylation of α-DG is
necessary both for its interaction with the extracellular matrix
(Michele and Campbell, 2003) and for its function as a receptor
for LCMV (Imperiali et al., 2005; Kunz et al., 2005) and LASV
(Kunz et al., 2005).
It is also clear that α-DG is not the only receptor to be used
by this family of viruses. Several isolates of LCMV have been
shown capable of infecting murine ES cells knocked-out for α-
DG, for example, variants WE2.2 and PBL364 gave wild-type
infection rates on the knockout cells (Smelt et al., 2001; Kunz et
al., 2004). Similarly, representative clade A (Parana) and clade
B (Amapari) New World viruses have been shown to infectmurine ES cells independently of α-DG (Spiropoulou et al.,
2002).
In this report, we used pseudotyped retroviral vectors to
examine cell tropism and receptor usage by both Old World and
New World viruses and in particular to further investigate the
requirement for α-DG. Our data demonstrate that α-DG plays
no role in the entry of the clade B viruses, JUNV and MACV,
and provide additional evidence that alternate, non-α-DG
receptor molecules can be used by LCMV.
Results
Generation of retroviral vectors pseudotyped with arenavirus
GPs
In order to examine GP–receptor interactions during
arenavirus entry, we generated a panel of retroviral vector
particles pseudotyped with the GPs from different pathogenic
arenaviruses. The use of pseudotyped vectors allows to examine
the arenavirus entry process in isolation from the rest of the
virus life cycle and to study BSL-4 pathogens under standard
BSL-2 laboratory conditions. The panel we used included the
Old World viruses LASVand LCMVand the New World clade
B viruses JUNV and MACV, together with the non-pathogenic
clade B virus Tacaribe (TACV) (Fig. 1). For LCMV, we used
GPs from both the prototypical Arm53b strain and a mutated
version of the protein with the substitution F260L at the C-
terminus of GP1 (Arm-F260L). This mutation corresponds to the
single change present in the GP of clone 13, an immunosup-
pressive variant of Arm53b (Salvato et al., 1991) that is reported
to have greater dependency on α-DG for entry (Smelt et al.,
2001).
Pseudotyped retroviral vectors were generated as previously
described (Christodoulopoulos and Cannon, 2001; Soneoka et
al., 1995). The vectors expressed GFP reporter genes, allowing
us to measure the efficiency of GP function by measuring
transduction rates (titer) by FACS analysis of target cells
incubated with the vector particles. All vector stocks were
initially titered on human 293A cells, which are efficiently
transduced by all of the different vectors used. The average
titers obtained for unconcentrated vector stocks are shown in
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pseudotyped with the Old World GPs were one order of
magnitude higher than those obtained with the NewWorld clade
B GPs. In addition, in each experimental pair tested, the titer of
the Arm-F260L vectors was slightly higher than those obtained
with the Arm53b vectors, although the difference was not
statistically significant when averaged out over 5 data sets.
Incorporation of arenavirus GPs into retroviral vector
particles
In order to examine whether the variation in titer on 293A
cells between the different pseudotyped vectors arose because
of differences in the efficiency of incorporation of GPs into
vector particles, we performed Western blot analysis on purified
vector particles. However, this analysis was complicated by the
fact that we could not find a broadly cross-reacting antibody that
recognized all of the arenavirus GPs used in this study. For
example, monoclonal antibody WE-83.6, directed against the
LCMV GP2 subunit, recognized only the LASV and LCMV
GP2 proteins (data not shown), while the anti-LASV GP1
monoclonal antibody L52-161-6 recognized only the LASV
protein (Fig. 3A). In contrast, the anti-JUNV monoclonal
antibody QD04 AF03 (Sanchez et al., 1989) recognized
proteins from both JUNV and LCMV, although it did not
cross-react with MACV, TACVor LASV proteins (Fig. 3B and
data not shown).
The proteins recognized by antibody QD04 AF03 for both
the JUNVand LCMV pseudotyped vectors were approximately
65 kDa (JUNV only) and 33 kDa. The 65 kDa species is
probably the uncleaved JUNV GPC precursor as this species
was more prevalent in cell lysates than in viral particles (data
not shown), but the identity of the 33 kDa protein was more
difficult to ascertain. Previously, the LCMV GP1 subunit has
been reported to run at 44 kDa and the GP2 subunit at 35 kDa
(Burns and Buchmeier, 1991), suggesting that the antibody is
recognizing GP2 subunits. However, QD04 AF03 has been
reported to recognize the JUNV GP1 subunit (York et al., 2005),
where the size of the JUNV GP1 and GP2 subunits was found toFig. 2. Titers of pseudotyped retroviral vectors on 293A cells. Titer was
determined by FACS analysis of cells to determine GFP expression, 48 h after
transduction, and the values shown are the mean ± SD for 3–6 independent
experiments.be approximately 33 and 35 kDa respectively. To determine
whether antibody QD04 AF03 was detecting the GP1 or GP2
subunits of JUNV and LCMV, we performed Western analysis
using deglycosylated viral proteins and compared the sizes of
the bands we saw to the predicted molecular weights for the
JUNV and LCMV GP1 and GP2 subunits. This analysis
revealed that the anti-JUNVantibody was probably recognizing
the GP1 subunits of both viruses (Fig. 3B). The finding that the
LCMV GP1 subunit runs at approximately 33 kDa in our
system instead of the previously reported 44 kDa was
unexpected. Possible explanations for this discrepancy include
the fact that previous studies have used native viruses rather
than pseudotyped vectors, and the different cell types used may
result in different glycosylation patterns that affect the size of
the mature cleaved GP1 subunit.
Interestingly, we detected a significant amount of unpro-
cessed JUNV GPC in viral particles, which was not seen with
the LCMV GP (Fig. 3B). This suggests that the lower titers
obtained for the clade B vectors on 293A cells could result from
less efficient processing of the GPC precursor, although it is
also possible that this difference arises from the ability of the
antibody to detect the JUNV but not the LCMV GPC precursor.
Alternatively, the differences between the titers of the clade B
and Old World pseudotypes could reflect the use of different
cellular receptors on the 293A cell surface. We note that the
one-log differences in titer that we observed between the clade
B and Old World vectors on 293A cells did not hold up for
every cell line we tested (see below).
As stated above, the LCMVArm-F260L variant always gave
slightly higher titers on 293A cells than the parental Arm53b
vectors, although this was not statistically significant (Fig. 2).
The presence of leucine or isoleucine at position 260 is typical
of the immunosuppressive strains of LCMV that cause
persistent infections in mice (Sevilla et al., 2000) and which
exhibit altered pathogenicity and tissue tropism in vivo (Ahmed
and Oldstone, 1988; Ahmed et al., 1984; Sevilla et al., 2000;
Smelt et al., 2001). Arm53b and clone 13 have been reported to
show large differences in their in vitro affinities for α-DG, with
clone 13 binding α-DG with 100–1000 times greater affinity
than Arm53b in virus overlay protein binding assays (VOPBAs)
(Sevilla et al., 2000; Smelt et al., 2001). In addition, clone 13 is
significantly more dependent on the presence of α-DG to infect
mouse ES cells (Kunz et al., 2004; Smelt et al., 2001).
To investigate the basis for the increase in titer resulting from
the F260L substitution, we examined whether the LCMVArm-
F260L GP was incorporated at higher efficiency into retroviral
vector particles. However, Western blot analysis revealed that
both the GP1 and GP2 subunits of Arm-F260L were incorpo-
rated into retroviral particles at significantly lower levels than
the Arm53b protein. Furthermore, higher levels of Arm-F260L
GP1 were observed in the lysates of transfected cells when
compared to Arm53b, which is consistent with a reduction in
the incorporation of Arm-F260L GP into retroviral particles. We
also observed that the F260L mutant consistently suppressed the
production of the retroviral vector particles, as measured by the
amount of MLV CA protein in the supernatant (Fig. 3C). Taken
together, these findings suggest that the single F260L change
Fig. 3. Incorporation of arenavirus GPs into retroviral vectors. (A) Western blots of pseudotyped retroviral vector particles, probed with anti-JUNV GP1 antiserum or
anti-LASV GP1 monoclonal antibody. The vector particles were concentrated by ultracentrifugation through a sucrose cushion. The positions of the GPC and GP1
subunits are indicated. (B) Western analysis of control and deglycosylated vector particles probed with the anti-JUNV GP1 antiserum. Comparison of the sizes of the
deglycosylated proteins (GPC* and GP1*) indicates that the antibody recognizes the GP1 subunits. (C) Comparison of levels of Arm53b and Arm-F260L GP in cell
lysates and retroviral particles using anti-JUNVGP1 antiserum and anti-LCMVGP2 monoclonal antibody. Significantly less Arm-F260L protein was incorporated into
virions, while showing equivalent or slightly increased levels in the corresponding cell lysates. Expression of the Arm-F260L GP also inhibited production of retroviral
particles, as revealed by the anti-MLV CA antibody.
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cells, despite its adverse effects on incorporation into retroviral
particles.
Differences in tropism of clade B and Old World pseudotyped
vectors
We next expanded our studies to examine the ability of the
vectors to transduce a variety of different cell types. To monitor
for any cell-specific effects on titer that were directed against
retroviral components, such as host restriction factors thatrecognize the retroviral core (reviewed in Nisole et al., 2005),
control vectors were included that were pseudotyped with the
vesicular stomatitis virus glycoprotein (VSV-G). We found that
the titers obtained varied with both the nature of the GP and the
cell type examined (Table 1). However, similar to our findings
with 293A cells, in several cell types that were permissive for
entry directed by all the GPs, we observed lower titers for the
JUNVand MACV GP pseudotyped vectors than the Old World
pseudotypes (HeLa, NIH3T3, mES, IEC-6 and CEF cells).
We noted that human T and B lymphocytes (CEM, Jurkat,
Nalm-6 and Raji cells) were completely resistant to LASV and
Table 1
Titers a of pseudotyped vectors on various cell lines
Glycoprotein Human Simian Rodent Avian
HeLa K562 CEM Jurkat Nalm 6 Raji Vero NIH3T3 mES CHOK1 IEC-6 CEF
VSV-G 8.0 × 104 2.5 × 104 8.5 × 105 6.5 × 105 2.0 × 105 2.4 × 104 4.7 × 105 4.8 × 104 2.2 × 105 2.4 × 105 2.1 × 105 3.9 × 105
Old World
LASV 2.2 × 105 1.9 × 105 0 0 0 0 7.3 × 103 4.1 × 104 1.4 × 105 3.0 × 104 1.1 × 105 7.4 × 103
LCMV-Arm53b 2.8 × 105 6.3 × 103 0 0 0 0 1.4 × 103 4.4 × 104 4.7 × 104 6.1 × 103 1.1 × 104 4.5 × 103
LCMV-Arm53b(F260L) 2.0 × 10
5 4.4 × 103 0 0 0 0 2.2 × 103 5.6 × 104 5.7 × 104 8.3 × 103 1.8 × 103 8.0 × 103
New World clade B
JUNV 8.0 × 103 1.3 × 104 1.8 × 104 3.2 × 103 1.4 × 102 0 2.1 × 103 4.3 × 103 5.9 × 103 1.2 × 103 4.0 × 103 9.8 × 102
MACV 3.0 × 104 1.3 × 103 3.1 × 104 2.2 × 103 2.5 × 103 2.7 × 102 8.7 × 103 1.6 × 102 2.2 × 102 2.1 × 102 1.6 × 102 8.2 × 102
a Titers of pseudotyped retroviral vectors were measured by FACS analysis of transduced cells, 48 hrs post-transduction, and are shown as number of GFP-positive
cells per ml of unconcentrated vector supernatant. Values shown are averages of 2–8 independent experiments.
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and MACV vectors. It has previously been reported that both
human and mouse lymphocytes are resistant to infection by
LCMV (Borrow and Oldstone, 1992; Imperiali et al., 2005),
probably because of incorrect glycosylation of α-DG in these
cells (Imperiali et al., 2005). The mouse T lymphocyte cell line
TIB-27 was also found to be resistant to transduction by LCMV
GP pseudotyped vectors (data not shown). Our data both
confirm and extend these findings by demonstrating that this
restriction can be conferred solely by the GP.
Lack of transduction of lymphocytes by Old World vectors
occurs despite the presence of dystroglycan
A possible explanation for the lack of titer of the Old
World vectors on human lymphocytes is that the cells do not
express sufficient quantities of the presumed Old World
receptor, α-DG. We addressed this possibility by performing
Western blot analysis to examine the levels of dystroglycan
on cells that were both permissive and non-permissive for
transduction. However, analysis of the levels of α-DG proved
technically difficult and we were unable to find an antibody
that specifically and unequivocally detected the α-DG subunit
on the complete panel of cell lines we looked at, despite
using three different antibodies, IIH6, VIA4-1 and 1B7 (data
not shown). To examine the levels of dystroglycan, we
therefore resorted to using an anti-β-DG antibody, 43DAG/
8D5, raised against the extreme C-terminus of the human DG
sequence. α-DG and β-DG are cleaved from the same
precursor protein and remain associated by non-covalent
interactions (Ibraghimov-Beskrovnaya et al., 1992). For
several of the cell lines tested, we observed 3 bands atFig. 4. β-DG expression in various cell types. Twenty micrograms of cell lysates was
murine ES cells, either knockout for DG expression (−/−) or the parental +/− cell liabout 43, 37 and 25 kDa (Fig. 4). A similar pattern has also
been observed in several carcinoma cell lines (Losasso et al.,
2000; Muschler et al., 2002), where the lower molecular
weight bands are thought to arise by proteolytic processing of
β-DG (Losasso et al., 2000; Yamada et al., 2001). Using this
antibody, we observed that all of the cell lines tested
expressed β-DG and that there was no correlation between
the ability of the arenavirus pseudotypes to enter cells and the
overall levels of β-DG expression. A similar conclusion was
reached in a recent study (Imperiali et al., 2005).
Despite the fact that we detected β-DG in human lymphoid
cell lines, we noted that the lymphocytes had lower levels than
the other human cell types (HeLa, 293A), suggesting the
possibility that the levels of DG could be suboptimal for
function as an arenavirus receptor in these cell types.
Accordingly, we transduced CEM cells with a retroviral vector,
pBabeDG, which contained the DG cDNA cloned into vector
pBabeNeo (Morgenstern and Land, 1990). Following confir-
mation that this treatment increased the levels of DG in both
CEM and control 293A cells (Fig. 5), we challenged the CEM-
pBabeDG population with LASV and LCMV-Arm53b pseudo-
typed vectors. However, we still observed no transduction (data
not shown).
We also examined whether CEM cells secreted an inhibitor
of cell entry, such as soluble α-DG that could bind to the GP and
interfere with subsequent cell binding and entry. However,
incubation of 293A cells with supernatant from CEM cells had
no effect on the titer of LASVor Arm53b pseudotyped vectors
(data not shown).
Finally, we examined whether lymphocytes could be
refractory to entry by Old World GP due to the presence of an
inhibitory factor. We generated heterokaryons between non-loaded in each lane, and the Western probed with anti-β-DG antibody. mES are
ne.
Fig. 5. Over-expression of DG. 293A or CEM cells were transduced with
retroviral vector pBabeDG, and the levels of DG examined 48 h later using
Western blotting and an anti-β-DG antibody. A significant increase in
expression was observed in both cell types.
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cell type, fusing the cells with PEG and FACS-sorting for the
doubly labeled heterokaryons, as described (Abada et al., 2005).
Subsequent challenge with LASVand Arm53b GP pseudotyped
vectors demonstrated that the heterokaryons could be readily
transduced by both vector types (Fig. 6). This finding rules out
the presence of a dominant negative factor in the CEM cells that
could act to inhibit the entry of the Old World viruses and
instead suggests that these cells are simply lacking expression of
a functional from of a necessary receptor or co-receptor
molecule. The recent suggestion that the correct glycosylationFig. 6. Heterokaryons formed between CEM and 293A cells are transduced by LASV
orange and green, respectively, fused with PEG, and the doubly staining heterokaryon
heterokaryon population following X-gal staining. Several dark blue staining nucle
galactosidase carried by the LASV GP vectors.of α-DG, and specifically O-mannosylation, is essential for its
activity as a receptor for LCMV (Imperiali et al., 2005; Kunz et
al., 2005) is in good agreement with our findings.
Requirement for α-DG in mouse ES cells
Our data so far strongly suggest that the New World clade B
viruses use a different receptor(s) than the Old World viruses. In
order to examine the requirements for α-DG in more detail, we
compared the titers of pseudotyped retroviral vectors on bothDG
knockout (−/−) and control heterozygous (+/−) murine ES cells
(Williamson et al., 1997). Standard retroviral vectors are very
inefficient at transducing murine ES cells, so it was necessary to
perform these experiments using MND-based retroviral vectors.
These vectors contain alterations in the long terminal repeat and
5′ untranslated regions of the MLV genome that combine to
increase transduction of murine ES cells (Challita et al., 1995).
We determined the titer of a panel of pseudotyped MND
vectors on the DG +/− and −/−murine ES cells. Since retroviral
vectors frequently give different titers when used to transduce
individual clones derived from the same population, presum-
ably due to a number of factors that can affect the efficiency of
transduction, we included VSV-G pseudotyped vectors as a
positive control. Although the cell surface receptor for VSV-G
is not clearly defined, VSV-G is not expected to be affected by
the presence or absence of α-DG. Using this control, we
observed consistent differences in titer for the VSV-G
pseudotyped vectors on the two cell lines, with the titers onGP pseudotyped vectors. (A) CEM and 293A cells were stained with CellTracker
s isolated by FACS (arrowed population). (B) A typical transduced cell from the
i are present in each cell, resulting from the expression of nuclear localized β-
Fig. 7. Effect of DG expression in murine ES cells on GP-directed titer. Titers of
GP pseudotyped vectors were measured on DG −/− and +/−murine ES cells and
the ratios determined. To correct for the different susceptibility of the two cell
lines to transduction by retroviral vectors, all ratios were made relative to the
VSV-G control in each experiment. Data shown are the mean ± SD for >5
independent experiments.
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+/− cells. To compensate for this and to allow direct comparison
of the effect of the GP on titer between the −/− and +/− cells, we
made all titers relative to the VSV-G control on the same cell
line (Fig. 7).
These analyses revealed several interesting findings. First,
we observed striking differences among the Old World viruses
in their requirements for α-DG. While LASV GP had an
absolute requirement for DG in murine ES cells, the two LCMV
GPs were only somewhat affected, suggesting that LCMV can
efficiently use an alternate receptor(s) to gain entry into murine
ES cells. Previously, it has been reported that the clone 13 strain
of LCMV has a significantly greater requirement for α-DG than
the parental Arm53b strain, and our data agree with these
findings since the F260L mutant was more sensitive to the loss of
DG than Arm53b (P = 0.027). However, the fact that we still
observed entry for vectors pseudotyped with the F260L mutant
GP suggests that there may be differences between the GP
pseudotyped vector system and the native virus that we are not
aware of or could simply reflect a difference in sensitivity in the
two systems.
This analysis also revealed that the clade B JUNV and
MACV GPs do not require α-DG for entry since the ratio of
titers on the two cell types was similar to the VSV-G control.
These data agree with our findings of broad tropism for the
clade B GP vectors on the panel of cell lines tested, including
their ability to infect lymphocytes. Together, they demonstrate
that the clade B viruses use receptor(s) other than α-DG.
Discussion
The identification of the cell surface receptor used by an
enveloped virus can help to explain its tropism and increase our
understanding of its pathogenicity and disease characteristics.
In the arenaviruses, α-DG was previously identified as a
receptor used by LASV, certain strains of LCMV and the New
World clade C viruses (Cao et al., 1998; Spiropoulou et al.,
2002). Although it is likely that LCMV can use other receptormolecules and that the clade A and B NewWorld viruses do not
use α-DG (Spiropoulou et al., 2002), no other molecules have
been proposed as receptors for this family.
Previous studies of arenavirus receptors have been per-
formed using a variety of in vitro assays, including binding
assays and VOPBAs, together with virus infections using α-DG
knockout murine ES cells (Borrow and Oldstone, 1992; Cao et
al., 1998; Kunz et al., 2004; Smelt et al., 2001; Spiropoulou et
al., 2002). The pseudotyped vector system that we have used in
this work has distinct advantages for analyzing virus entry and
receptor usage, including the ability to analyze the role of GP in
the absence of other viral proteins. Importantly, these analyses
can be performed under BSL-2 conditions, and similar systems
have been widely used for other pathogenic enveloped viruses
(Bartosch et al., 2003; Lin and Cannon, 2002; Wool-Lewis and
Bates, 1998). Since the read-out in this system is an entry event
(transduction), it is also likely to be a more accurate measure of
functional GP–receptor interactions than can be obtained using
in vitro assays since these are not always predictive of entry into
cell lines. For example, the LCMV isolate PBL364 shows high
affinity binding to α-DG in vitro yet has almost wild-type
kinetics of infection on α-DG −/− murine ES cells (Kunz et al.,
2004), and VOPBA assays performed on rat intestinal epithelial
cells were negative for Arm53b binding (Borrow and Oldstone,
1992), despite our finding that Arm53b GP pseudotyped vectors
can readily transduce these cells.
The pseudotyped retroviral vector system also has advan-
tages when compared to studies of entry made using infectious
virus. Apart from the biosafety issues involved, viral infections
are a complex system, where variations in tropism can be
caused by proteins other than the GP. In addition, the
arenaviruses have a short replication cycle coupled to a high
mutation frequency of approximately 10−3 to 10−5 misincor-
porations per nucleotide site and round of copying (Domingo
and Holland, 1997), leading to the generation of a large
population of variants (Ruiz-Jarabo et al., 2003). Consequently,
the biological properties of the variants may be very different
from the original isolate used to initiate a culture or inoculate a
host. Finally, such studies do not rule out the possibility that the
lack of replication in certain cell lines is due to other, post-entry
blocks to the arenavirus life-cycle.
Our study confirms and extends previous findings reported
for arenavirus receptor usage by the Old World viruses. In
agreement with Kunz et al. (2005), we found that LASV has an
absolute requirement for α-DG in murine ES cells. However, in
the context of pseudotyped retroviral vectors, we observed that
the GP from the prototypic Arm53b isolate of LCMV was still
able to transduce α-DG −/− murine ES cells at approximately
30% the level of cells expressing α-DG. Previous studies have
also reported lower levels of infection for LCMV isolates in the
absence of α-DG (Kunz et al., 2003; Smelt et al., 2001).
However, introducing the mutation F260L into the Arm53b GP,
which mimics the change present in the clone 13 virus isolate,
did not completely abolish transduction of −/− cells, although
the ratio of transduction on the −/− to +/− cells was significantly
lower than observed for the Arm53b isolate, indicating a greater
dependence on α-DG for efficient entry.
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an alternate receptor on murine ES cells that can be used by
LCMV but not by LASV. It is not clear at present whether this
molecule represents a distinct receptor molecule in its own right
or whether it normally functions as a co-receptor to α-DG that
can be used, albeit less efficiently, in the absence of α-DG. Such
a situation is known to exist in the primate immunodeficiency
viruses, where the viral Env binds sequentially to both a primary
receptor, CD4, and a co-receptor molecule such as CCR5, but
where CD4-independent entry is observed for certain isolates of
both SIV and HIV-1 (Dumonceaux et al., 1998, Edinger et al.,
1997). Clone 13 is reported to display both higher affinity for α-
DG and a greater dependence on α-DG for entry than the
Arm53b isolate (Kunz et al., 2004; Smelt et al., 2001). These
two attributes are consistent with a model whereby the F260L
substitution could make the GP more dependent on α-DG
binding to allow subsequent co-receptor binding, and thereby
making α-DG-independent entry more difficult for this strain.
The marked discrepancy in the behavior of the LASV and
LCMV pseudotyped vectors on α-DG −/− murine ES cells was
not observed on any other cell type we examined, including
other rodent cell lines (NIH3T3, IEC-6, CHO-K1). Instead,
these Old World pseudotypes generally behaved in the same
way, with titers falling in the same order of magnitude. Probably
this reflects the dominance of α-DG as a receptor for these
viruses.
For the Old World virus pseudotypes, we also consistently
observed that T and B lymphocytes were non-permissive for
entry. Recent work has demonstrated the importance of correct
O-mannosylation of α-DG in order for it to serve as an
arenavirus receptor (Imperiali et al., 2005; Kunz et al., 2005),
and it is probable that the glycosylation state of DG in these
cells underlies the block to arenavirus entry. Furthermore,
binding studies that we have performed using a LASV GP1
immunoadhesin and the T lymphocyte cell line CEM revealed
that GP1 does not bind to these cells (Reignier et al.,
unpublished observations), which is consistent with this
hypothesis. Interestingly, the lack of transduction of lympho-
cytes by the Old World vectors suggests that the alternate
receptor present on murine ES cells that LCMV GP can use is
not available on either human or murine lymphocytes.
For the New World clade B viruses that we studied, entry
into murine ES cells directed by the JUNVand MACV GPs was
unaffected by the loss of α-DG. These two GPs displayed a very
broad tropism, transducing human, simian, rodent and avian cell
lines and were able to enter human lymphocytes. Together,
these data suggest that the receptor(s) that they use are likely to
be distinct from any alternate receptors that could be utilized by
LCMV in the absence of α-DG. The ability of the JUNV and
MACV pseudotypes to transduce human lymphocytes is at odds
with their in vivo tropism, where cells of the monocyte/
macrophage lineage are infected but not lymphocytes (Geisbert
and Jahrling, 2004). However, since viral tropism results from a
complex set of interactions between a virus and a host cell, the
ability of the JUNV and MACV GPs to direct entry into a cell
does not necessarily predict a productive infection in that
particular tissue in a patient.Overall, our study reveals that receptor usage by the
arenaviruses may be more complex than was previously
appreciated. The search for the clade B receptor(s) and the
alternate or co-receptors used by LCMV is an important goal for
understanding more about the pathogenicity of these viruses.
Materials and methods
Cell lines
293A, 293T, Vero, HeLa, Cos-7, NIH 3T3, CHOK1, TIB-
27 and IEC-6 cells were maintained in Dulbecco's modified
Eagle's medium (DMEM) (Mediatech, Herndon, VA), with
10% fetal bovine serum (FBS) (Hyclone, Logan, UT) and
2 mM glutamine (Gibco BRL, Grand Island, NY). Raji,
Jurkat, CEM and Nalm-6 cells were maintained in RPMI
(Irvine Scientific, Santa Ana, CA) supplemented with 10%
FBS and 2 mM glutamine. Dystroglycan-null knockout (−/−)
and heterozygous control (+/−) R1 murine embryonic stem
(ES) cells (Williamson et al., 1997) were generously
provided by Dr. Kevin Campbell, University of Iowa.
These cells were grown in DMEM supplemented with 20%
FBS, 2 mM glutamine, 1 mM non-essential amino acids,
0.001% β-mercaptoethanol and 103 units/ml of LIF
(ESGRO, Chemicon, Temecula, CA). All cells were main-
tained in 5% CO2 except the TIB-27 cells which were
maintained in 10% CO2.
Arenavirus glycoproteins
The GP from the Armstrong 53b (Arm53b) strain of LCMV
(Southern et al., 1987) was kindly provided by Gabor Veres
(Cell Genesys), expressed from the CMV immediate early
promoter in vector pCI (Promega, Madison, WI). When
compared to the original database sequences of Arm53b GP
(accession number NP_6948514), two differences were found,
R177A and A313E. These changes are also present in two other
database sequences for LCMV GP (accession numbers
AAX49341.1 and P09991) and were also observed in two
independent isolates of Arm53b that we cloned from a virus
stock kindly provided by Dr. M. Suresh (University of
Wisconsin, Madison). The clone 13 variant of LCMV-
Arm53b GP contains the substitution F260L (Salvato et al.,
1988), and this mutation was introduced into the Arm53b GP to
generate Arm53b-F260L. The GP from LASV (Josiah strain,
accession no. AY628203) was expressed in vector pCAGGS
(Niwa et al., 1991). A sequence corresponding to the reported
database sequence of JUNV GP (Parodi strain, accession no.
U70799) was derived from genomic fragments of the JUNV S
strand (Albarino et al., 1997) and cloned into the CMV
immediate early promoter expression plasmid pSA90 (Soneoka
et al., 1995). Tacaribe virus (TACV) GP was cloned by RT-PCR
from total RNA isolated from infected Vero cells and cloned
into the CMV immediate early promoter expression vector
pCAGGS. It differs from the database sequence for strain TRVL
11598 (accession number P31840) at two positions, R233H and
E446R. The GP from MACV (Carvallo strain, accession no.
119T. Reignier et al. / Virology 353 (2006) 111–120AY129248) was synthesized as a codon optimized open-reading
frame and cloned into the pCAGGS.
Retroviral vector production and titer determination
Retroviral vectors displaying arenavirus GPs were produced
by transient transfection of plasmids pCgp (Han et al., 1998),
pMND-eGFP (Zheng et al., 2004) or pCnBg (Han et al., 1998)
and the appropriate GP expression plasmid into 293T cells,
essentially as described (Christodoulopoulos and Cannon,
2001; Han et al., 1998). The pCgp plasmid expresses murine
leukemia virus (MLV) Gag-Pol, and plasmids pMND-eGFP and
pCnBg are retroviral vector genomes expressing enhanced
green fluorescence protein (eGFP) or nuclear-localized β-
galactosidase, respectively, as reporter genes. Retroviral vector
supernatants were harvested 48 h post-transfection filtered
through a 0.45 mm filter (Millipore Corp., Bedford, MA), and
aliquots were stored at −80 °C. Titers were determined by
incubation of serially diluted vector stocks with target cells for
48 h followed by calculation of percent positive cells, either by
X-gal staining for β-galactosidase expression (Christodoulo-
poulos and Cannon, 2001) or by FACS analysis for eGFP
expression.
Western blot analysis
For detection of β-dystroglycan (β-DG), cells were lysed
in lysis buffer (20 mM Tris–HCl [pH 7.5], 1% Triton X-100,
0.05% sodium dodecyl sulfate [SDS] containing 5 mg/ml
sodium deoxycholate, 150 mM NaCl and 1 mM phenyl-
methylsulfonyl fluoride [Sigma]) at 4 °C for 10 min,
centrifuged in an Eppendorf microfuge at 16,000 × g for
10 min and the cleared supernatants were diluted 1:1 in 2 ×
SDS gel loading buffer (Biorad, Hercules, CA) plus 5% 2-
mercaptoethanol, boiled for 10 min and electrophoresed in 8–
16% polyacrylamide gels (Biorad). The proteins were
transferred to an Immobilon P polyvinylidene fluoride transfer
membrane (Millipore Corp., Bedford, MA) and blocked
overnight at 4 °C with blocking buffer (5% dried milk in
PBST [PBS {pH 7.4}, 0.1% Tween 20]). β-DG was detected
using the 43DAG1/8D5 antibody (Novocastra Laboratories
Ltd, Newcastle upon Tyne, UK) at a 1:50 dilution in blocking
buffer followed by horseradish-peroxidase-conjugated goat
anti-mouse IgG (1:10,000) (Pierce, Rockford, IL). Specific
proteins were visualized using the enhanced chemilumines-
cence detection system (Amersham Biosciences Corp., Piscat-
away, NJ).
Viral GPs in either cell lysates or retroviral particles were
detected by Western blot analysis of cell lysates or
concentrated virus supernatants, essentially as described
(Christodoulopoulos and Cannon, 2001). The antibodies
used were the anti-LASV GP monoclonal antibody L52-
161-6 (Ruo et al., 1991) at a 1:10,000 dilution, the anti-JUNV
GP monoclonal antibody QD04 AF03 (Sanchez et al., 1989;
York et al., 2005) at a 1:2000 dilution, the anti-LCMV GP2
monoclonal antibodies WE-83.6 (Parekh and Buchmeier,
1986) at 1:100 dilution and 2704 (Parekh et al., 1989) at a1:3000 dilution. Retroviral vector particles were detected
using the goat anti-Rauscher MLV CA antiserum (Quality
Biotech, Camden, NJ) at a 1:10,000 dilution. Where required,
viral proteins were deglycosylated by incubation with peptide
N-Glycosidase F (PNGase F; New England Biolabs, Ipswich,
MA) for 90 min at 37 °C, using 750 units of enzyme for
20 μg of total protein.
Heterokaryon analysis
CEM and 293A cells were stained by incubation for 45 min
at 37 °C in growth media containing 1 mM CellTracker green
(Molecular Probes, Eugene, OR) for CEM cells, or 10 mM
CellTracker orange (Molecular Probes) for 293A cells,
essentially as described (Abada et al., 2005). A mixture of
1 × 107 of each labeled cell type was fused by the addition of
1 ml of 50% polyethylene glycol (PEG) with a molecular mass
of 3000 Da (Sigma) in 2% glucose, as described (Abada et al.,
2005). Following overnight incubation, the doubly labeled
population was sorted using a FACS DIVA (Becton Dickinson,
San Jose, CA) with an excitation laser frequency of 488 nm and
emission detected at 525 nm. The sorted cells were plated in 6-
well plates, and 48 h later, the heterokaryons were challenged
with LASV or LCMV-Arm53b pseudotyped retroviral vectors
expressing nuclear localized β-galactosidase (vector pCnBg).
Staining with X-gal (Han et al., 1998) and microscopic
examination were used to determine whether the heterokaryons
had been transduced.
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